No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ADPT240719P5000
- 0.90
- -0.08-8.16%
15min DelayClose Jul 12 15:59 ET
0.90High0.90Low
0.90Open0.98Pre Close1 Volume401 Open Interest5.00Strike Price90.00Turnover0.00%IV-2.50%PremiumJul 19, 2024Expiry Date1.00Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.16Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Insiders At Adaptive Biotechnologies Sold US$664k In Stock, Alluding To Potential Weakness
Quite a few Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insiders sold their shares over the past year, which may be a cause for concern. When analyzing insider transactions, it is usually
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor
On Monday, Cathie Wood-led Ark Invest made a notable investment in Palantir Technologies Inc (NYSE:PLTR), a move that comes as the AI sector gains momentum.
Express News | Adaptive Biotechnologies Says Its Next-generation Sequencing-based ClonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment With ClonoSEQ To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
SEATTLE, May 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical
Comments
Good volume move up. Small caps like adaptive biotechnologies are moving after Nvidia and other big techs took a break.
Should see higher prices from here.
Should see higher prices from here.
3
$Adaptive Biotechnologies(ADPT.US$ Adaptive Biotechnologies Says Its Next-generation Sequencing-based ClonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting
The meeting will be taking place from May 31-June 4 in Chicago. Company will also present at the European Hematology Association (EHA) Hybrid Congress taking place June 13-16 in Madrid and virtually...
The meeting will be taking place from May 31-June 4 in Chicago. Company will also present at the European Hematology Association (EHA) Hybrid Congress taking place June 13-16 in Madrid and virtually...
1
Will they be as good as Ardelyx? Hopefully.
Ardelyx price skyrocketed after good earnings. The tide could be turning for biopharm, biotech stocks.
Ardelyx price skyrocketed after good earnings. The tide could be turning for biopharm, biotech stocks.
Recent insider selling at Adaptive Biotechnologies and lack of insider buying in the past year may deter potential investors, despite insiders owning significant shares.
$Adaptive Biotechnologies(ADPT.US$ Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene's Lymphoid Malignancy Pipeline
3
Read more